These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35947299)

  • 1. Renin and electrolytes indicate the mineralocorticoid activity of fludrocortisone: a 6 year study in primary adrenal insufficiency.
    Ceccato F; Torchio M; Tizianel I; Peleg Falb M; Barbot M; Sabbadin C; Betterle C; Scaroni C
    J Endocrinol Invest; 2023 Jan; 46(1):111-122. PubMed ID: 35947299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency.
    Flad TM; Conway JD; Cunningham SK; McKenna TJ
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):529-34. PubMed ID: 8977748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
    Baumstark ME; Nussberger J; Boretti FS; Baumstark MW; Riond B; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2014; 28(5):1471-8. PubMed ID: 25274440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.
    Cohen N; Gilbert R; Wirth A; Casley D; Jerums G
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1411-5. PubMed ID: 8636343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Renin: A Useful Marker for Mineralocorticoid Adjustment in Patients With Primary Adrenal Insufficiency.
    Piazzola C; Dreves B; Albarel F; Nakache J; Morera J; Joubert M; Brue T; Reznik Y; Castinetti F
    J Endocr Soc; 2024 Sep; 8(11):bvae174. PubMed ID: 39416427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency.
    Pofi R; Prete A; Thornton-Jones V; Bryce J; Ali SR; Faisal Ahmed S; Balsamo A; Baronio F; Cannuccia A; Guven A; Guran T; Darendeliler F; Higham C; Bonfig W; de Vries L; Bachega TASS; Miranda MC; Mendonca BB; Iotova V; Korbonits M; Krone NP; Krone R; Lenzi A; Arlt W; Ross RJ; Isidori AM; Tomlinson JW
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31613957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy.
    Esposito D; Pasquali D; Johannsson G
    J Clin Endocrinol Metab; 2018 Feb; 103(2):376-387. PubMed ID: 29156052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid substitution and monitoring in primary adrenal insufficiency.
    Quinkler M; Oelkers W; Remde H; Allolio B
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):17-24. PubMed ID: 25617169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and therapy surveillance in Addison's disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone.
    Oelkers W; Diederich S; Bähr V
    J Clin Endocrinol Metab; 1992 Jul; 75(1):259-64. PubMed ID: 1320051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid replacement in Addison's disease.
    Thompson DG; Mason AS; Goodwin FJ
    Clin Endocrinol (Oxf); 1979 May; 10(5):499-506. PubMed ID: 476980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing treatment adherence is crucial to determine adequacy of mineralocorticoid therapy.
    Pofi R; Bonaventura I; Duffy J; Maunsell Z; Shine B; Isidori AM; Tomlinson JW
    Endocr Connect; 2023 Aug; 12(9):. PubMed ID: 37410094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement.
    Oelkers W; L'age M
    Klin Wochenschr; 1976 Jul; 54(13):607-12. PubMed ID: 940296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that patients with Addison's disease are undertreated with fludrocortisone.
    Smith SJ; MacGregor GA; Markandu ND; Bayliss J; Banks RA; Prentice MG; Dorrington-Ward P; Wise P
    Lancet; 1984 Jan; 1(8367):11-4. PubMed ID: 6140341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acute effect of a mineralocorticoid receptor agonist on corticotrope secretion in Addison's disease.
    Berardelli R; Karamouzis I; D'Angelo V; Fussotto B; Minetto MA; Ghigo E; Giordano R; Arvat E
    J Endocrinol Invest; 2016 May; 39(5):537-42. PubMed ID: 26450146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4 years of age.
    Bonfig W; Schwarz HP
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):871-5. PubMed ID: 24818525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stress-Dosed Glucocorticoids and Mineralocorticoids Before Intensive Endurance Exercise in Primary Adrenal Insufficiency.
    Bonnecaze AK; Reynolds P; Burns CA
    Clin J Sport Med; 2019 Nov; 29(6):e73-e75. PubMed ID: 31688185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of renin assays in selecting fludrocortisone dose in children with adrenal disorders.
    Morris TJ; Whatmore A; Hamilton L; Hird B; Kilpatrick ES; Tetlow L; Clayton P
    Endocr Connect; 2024 Feb; 13(2):. PubMed ID: 38165389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of adrenal insufficiency in different clinical settings.
    Hahner S; Allolio B
    Expert Opin Pharmacother; 2005 Nov; 6(14):2407-17. PubMed ID: 16259572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of carbenoxolone on the plasma renin activity and hypothalamic-pituitary-adrenal axis in congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
    Irony I; Cutler GB
    Clin Endocrinol (Oxf); 1999 Sep; 51(3):285-91. PubMed ID: 10469007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention.
    Krishna GG; Kapoor SC
    Kidney Int; 1993 May; 43(5):1097-103. PubMed ID: 8510388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.